Mirum Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Product sales, net | $185,721 | $133,010 | $521,846 | $372,380 |
| Operating expenses: | ||||
| Cost of sales | 35,172 | 25,537 | 94,325 | 71,976 |
| Research and development | 107,931 | 42,960 | 296,369 | 130,071 |
| Acquired in-process research and development | 13,500 | — | 756,237 | 5,000 |
| Selling, general and administrative | 88,864 | 61,910 | 266,663 | 182,902 |
| Total operating expenses | 245,467 | 130,407 | 1,413,594 | 389,949 |
| (Loss) income from operations | (59,746) | 2,603 | (891,748) | (17,569) |
| Other income (expense): | ||||
| Interest income | 4,688 | 3,251 | 11,940 | 9,307 |
| Interest expense | (1,606) | (3,606) | (7,840) | (10,791) |
| Other income (expense), net | 16,436 | 395 | (7,798) | 2,589 |
| Net (loss) income before provision for income taxes | (40,228) | 2,643 | (895,446) | (16,464) |
| Provision for (benefit from) income taxes | 538 | (262) | 2,702 | 1,169 |
| Net (loss) income | $(40,766) | $2,905 | $(898,148) | $(17,633) |
| Net (loss) income per share, basic | $(0.62) | $0.06 | $(14.35) | $(0.35) |
| Net (loss) income per share, diluted | $(0.87) | $0.05 | $(14.35) | $(0.35) |
| Weighted-average shares of common stock used to compute net loss per share, basic | 65,527,401 | 50,639,231 | 62,608,658 | 49,758,104 |
| Weighted-average shares of common stock used to compute net loss per share, diluted | 66,049,776 | 56,993,841 | 62,608,658 | 49,758,104 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.